ADVANCED SOLID TUMORS

This early-phase study tests a new drug called AMG 355, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumor…

This study tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C gene change. The main goals are to check safety and how well the drug works at shrinking or controlling tumors. About 610 participa…

This early-phase study tests an experimental mRNA medicine, mRNA-4106, in people with advanced solid tumors that have not responded to standard treatments. The study aims to check the safety and tolerability of the drug when given alone or with another cancer therapy called a che…

This early-phase study is testing a new drug called Debio 0123 in 66 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. Participants receive the dr…

This study tests a new drug called ASP1570 in adults with advanced solid tumors that have spread or can't be removed. The drug is given alone or with other cancer treatments like pembrolizumab, chemotherapy, or both. The main goals are to check safety, see how well people tolerat…

This early-stage study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This early-phase study tests an investigational drug called ABBV-400 in about 520 adults with advanced solid tumors, including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose, either alone or combined with another drug (bevacizumab). …

This early-phase study tests a new drug, BMS-986484, alone or with another drug (nivolumab) in people with advanced solid tumors like lung, colorectal, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants wil…

This study tested the drug pembrolizumab in over 1,600 people with various advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink or control the tumors. The trial focused on identifying which patients were most likel…

This early-stage trial tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also seeing if the combination can shrink tumors o…

This early-phase study tests a new form of the chemotherapy drug topotecan, wrapped in a liposome (a tiny fat bubble), to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The study includes cancers like ovarian,…

This study tests whether adding a new drug called NP137 to standard immunotherapy can help control advanced solid tumors that are stable or not responding well. About 57 adults with various solid tumors will receive NP137 alongside their usual PD-1/PD-L1 blocker. The goal is to s…

This study tests a new drug called CGT4859 in people with bile duct cancer (cholangiocarcinoma) or other advanced solid tumors that have specific genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About …

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth. About 112 participants w…

This early-stage study tests a new drug, BAY 2965501, that aims to activate the body's immune T-cells to fight advanced solid tumors (like certain skin, kidney, stomach, and lung cancers). The study involves about 284 participants and will test the drug alone or combined with oth…

This study tests a new drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (cancers that have spread). The drug is given alone or with other standard cancer medicines. The main goals are to check safety, find the best dose, and see if it…

This early-phase study tests an experimental drug, ABBV-706, alone or with other treatments, in adults with advanced solid tumors like small cell lung cancer and brain tumors. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 288 partici…

This study tests the safety of a new drug, PRL3-ZUMAB, in people with advanced solid tumors or blood cancers that have not responded to standard treatments. It is the first time this drug is given to humans, after showing promise in animal tests. The main goal is to find the safe…

This early-phase study tests a new drug called QTX3544, alone or with another drug, in people with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety and find the right dose. About 237 adults with tumors that have not responded to…

This early-phase trial tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. It is given alone or with another immunotherapy (pembrolizumab) to about 129 adults whose cancers have not responded to standard …

This study follows people with advanced solid tumors who are already getting benefit from the cancer drug spartalizumab (alone or with other treatments) in earlier Novartis studies. The goal is to keep monitoring safety and side effects over a longer time. About 120 participants …

This study tests a new drug called GDC-6036 in people with advanced cancers (like lung or colon cancer) that have a specific gene change called KRAS G12C. The goal is to find safe doses and see if the drug works alone or with other treatments. About 500 adults will take part in t…

This early-phase study tests an experimental drug called ZW191 in about 145 people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to deliver chemotherapy directly to cancer cells that have a specific marker (folat…

This early-stage study tests a new drug called HRS-6209 in 56 adults with advanced solid tumors who have exhausted standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have measurable tumors an…

This early-phase study tests a new treatment called hV01, a modified virus designed to infect and kill cancer cells while boosting the immune system. It is for people with advanced solid tumors that have not responded to standard therapies. The main goal is to check the safety of…

This is a first-in-human study to test the safety and find the right dose of an experimental pill called ATV-1601. It is for adults with advanced solid tumors, including certain breast, gynecologic, and prostate cancers, that have a specific genetic change called an AKT1 E17K mut…